Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program
Open Access
- 16 June 2026
- journal article
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (16) , 1-10
Abstract
Time-to-progression ratio (TTPr) measures intra-patient treatment benefit by comparing disease control on study treatment with that of the immediately preceding therapy. Its prognostic validity in the immune checkpoint inhibitor (ICI) era remains uncertain. We performed a pooled patient-level analysis of eight phase II trials. Associations between TTPr, TTP on prior therapy (TTP1), and on-study TTP (TTP2/ PFS), objective response rate (ORR), with overall survival (OS) were evaluated using Cox regression. Landmark analyses at 6-months were used to mitigate guarantee-time bias. Among 246 evaluable participants, median TTP1 and TTP2 were 3.9 and 2.1 months, respectively, with poor correlation (r = 0.02). TTPr was not associated with OS (TTPr ≥1.3 vs p < 0.001); (response vs non-response: HR 0.19, 95% CI 0.07-0.52, p = 0.001) and remained independently associated with OS in multivariable analyses. Findings were consistent across ICI and non-ICI trials. TTPr is not a robust prognostic measure in platform trials. Although this raises concern regarding its validity as a surrogate endpoint for OS, formal evaluation requires randomized treatment comparisons.Keywords
Funding Information
- Faculty of Medicine and Health, University of Sydney (SC4212)
This publication has 27 references indexed in Scilit:
- 2715P Phase II trial of tildrakizumab in treatment-refractory bone and soft tissue sarcomasAnnals of Oncology, 2025
- 1544P A phase II trial of palbociclib and avelumab in advanced solid tumours with CDK4/6 pathway alterationsAnnals of Oncology, 2025
- 973P Phase II trial of Vismodegib in advanced cancers with Hedgehog pathway alterationsAnnals of Oncology, 2025
- Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimensESMO Open, 2023
- The progression-free survival ratio as outcome measure in recurrent ovarian carcinoma patients: Current and future perspectivesGynecologic Oncology Reports, 2022
- Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indicationsESMO Open, 2021
- FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019JAMA Internal Medicine, 2020
- Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid CancersJAMA Oncology, 2018
- Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mgEuropean Journal of Cancer, 2005
- Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinomaAnnals of Oncology, 2001